Assenagon Asset Management
MNTA

Assenagon Asset Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Assenagon Asset Management’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-103,365
Closed -$1.29M – 1163
2019
Q2 		$1.29M Buy
+103,365
New +$1.37M 0.01% 654

Other funds holding MNTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Assenagon Asset Management's MNTA Position: Q3 2019 in Review

Assenagon Asset Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2019, closing a stake of 103,365 shares — an estimated $1.29M sold.

Assenagon Asset Management first reported a position in MNTA in Q2 2019 and held it in 1 quarter. The position peaked at $1.29M in Q2 2019. 154 funds tracked by Wall St. Rank hold MNTA as of Q3 2019.

  • Assenagon Asset Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Assenagon Asset Management sold 103,365 Momenta Pharmaceuticals, Inc. shares in Q3 2019, an estimated $1.29M.
  • Assenagon Asset Management first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Assenagon Asset Management's Momenta Pharmaceuticals, Inc. position peaked at $1.29M in Q2 2019.
  • 154 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2019.

Based on Assenagon Asset Management's 13F filing for Q3 2019, filed 16 Oct 2019.